ClinicalTrials.gg
CompletedNCT05257044Updated Jun 2, 2026

Acute Effects of Cannabigerol

A Phase 1 interventional study of Cannabigerol and Placebo in Focus: To Examine Acute Effects of CBG on Anxiety, Stress, and Cognition, sponsored by Washington State University. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-02.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Washington State University · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the effects of hemp-derived cannabigerol (CBG) on anxiety, stress, mood, and cognition. Further, the severity of various side effects of CBG (sleepiness, dry mouth, dry eyes, increased appetite) will be assessed. As such, the study is focused on better understanding some of the potentially beneficial and detrimental effects of CBG on humans.

Read the detailed description

Recruitment: Prospective participants aged 21+ who have experience using cannabis-based products will be recruited from our previous survey of CBG users, from a CBG distributor in Washington (WA) state, and via social media. These prospective participants will complete a brief online survey to determine they meet eligibility requirements. Specifically, to be eligible they will need to be 21+ years of age, reside in WA state, own a smartphone, have access to a private environment where they can access a computer with a webcam connected to a high-quality and stable internet, speak fluent English, be literate, have experience using cannabis-based products without serious adverse reactions, and be free of serious psychiatric disorders, neurological and other serious medical conditions, pregnancy, or breastfeeding, or use of illicit substances in past 2 months.

Pre-Study Preparation: Eligible participants will be contacted via email and will be asked to schedule a brief 10-minute Zoom meeting to discuss the study requirements and provide informed consent. During this brief Zoom call participants will be provided with the contact information of a CBG distributor in WA state so that they can obtain a small vial of CBG tincture (20 mg) and a small vial of placebo tincture that will be color-coded by the distributor and provided to participants at no cost. The researchers will not directly provide or handle the products. Rather, participants will obtain the product on their own without compensation. Participants will also be asked to download an app called DRUID the day prior to their testing session. This app is designed to assess cognitive and motor impairment. Finally, participants will be asked to abstain from using CBG or any cannabis products for at least 24 hours prior to participation in each testing session. Questions will also be solicited and answered at this time, informed consent will be provided online and then the two testing sessions will be scheduled.

Testing Session 1: Participants will be randomly assigned to ingest either the CBG tincture (20 mg) or placebo tincture orally in the first testing session. Next, they will provide a series of baseline ratings of their mood, anxiety, and stress using 0 to 10 rating scales and the State Form of the State-Trait Anxiety Inventory. They will also provide baseline ratings of levels of intoxication and potential side effects (dry mouth, dry eyes, sleepiness, increased appetite, intoxication, heart palpitations/ racing heart) using 0 to 10 rating scales.

Once all of these baseline measures have been obtained, the research assistant (RA) will ask if she can observe the participant ingesting one of the products using a double-blind procedure (vials will be color-coded and only the PI will know which color is used to code the two products). Next, participants will complete an online survey to obtain information on demographic characteristics, cannabis and CBG use patterns, depression, anxiety, and stress. This will also provide time for the CBG to take effect. After participants complete the approximately 20-minute survey they will be asked to obtain ratings of their mood, anxiety, and stress using 0 to 10 rating scales and the State Form of the State-Trait Anxiety Inventory. The investigators will also assess potential side effects (dry mouth, dry eyes, sleepiness, increased appetite, intoxication, heart palpitations/racing heart) and drug effects using 0 to 10 rating scales. Next, participants will complete the Trier Social Stress Test and then will complete ratings of their mood, anxiety, and stress using 0 to 10 rating scales and the State Form of the State-Trait Anxiety Inventory. Next, they will complete the California Verbal Learning Test II, and the cognitive and motor tests on the DRUID app. Finally, they will complete ratings of their mood, anxiety, and stress using 0 to 10 rating scales and the State Form of the State-Trait Anxiety Inventory. The investigators will also assess potential side effects (dry mouth, dry eyes, sleepiness, increased appetite, intoxication, heart palpitations/racing heart) using 0 to 10 rating scales. This entire process (completing testing session 1) will take approximately 90-minutes total.

Testing Session 2: Approximately one-week later participants will complete the second testing session which will be identical to the first testing session with the exception of the product they will ingest. Specifically, those that ingested the CBG tincture in session 1 will ingest the placebo in session 2 and those that ingested the placebo in session 1 will ingest the CBG tincture in session 2. Also, at the end of the second testing session participants will be debriefed. Completing testing session 2 will also take approximately 90-minutes total. As such completing both sessions will require a total of 3 hours.

02

Conditions studied

  • Focus: To Examine Acute Effects of CBG on Anxiety, Stress, and Cognition

Browse trials for

Keywords

  • Anxiety, Stress, Memory, Mood, Cognition, Side Effects
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's enrollment of 38 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Washington State University is the lead sponsor of 83 studies on the registry; 16 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 21+ years of age
  • reside in Washington state
  • own a smartphone
  • have access to a private environment where they can access a computer with a webcam connected to a high-quality and stable internet
  • speak fluent English
  • be literate
  • have experience using cannabis-based products without serious adverse reactions

Exclusion criteria

Exclusion Criteria

  • serious psychiatric disorders (e.g., psychotic disorder, bipolar disorder)
  • neurological and other serious medical conditions including head injury
  • pregnancy, or breastfeeding
  • use of illicit substances in past 2 months
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    CBG

    Participants will ingest 20 mg of CBG tincture in this arm

    Drug: Cannabigerol

  • Placebo comparator
    Placebo

    Participants will ingest 20 mg of placebo tincture in this arm

    Other: Placebo

Interventions

  • Participants will ingest CBG and placebo in a double-blind randomized cross-over design

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in Mood

    Participants will provide ratings of their mood using 0-10 scales

    Time frame: Change from baseline to approx. 20 minutes after CBG/placebo use

  2. Change in Mood

    Participants will provide ratings of their mood using 0-10 scales

    Time frame: Change from baseline to approx. 40 minutes after CBG/placebo use

  3. Change in Mood

    Participants will provide ratings of their mood using 0-10 scales

    Time frame: Change from baseline to approx. 60 minutes after CBG/placebo use

  4. Change in Stress

    Participants will provide ratings of their stress using 0-10 scales

    Time frame: Change from baseline to approx. 20 minutes after CBG/placebo use

  5. Change in Stress

    Participants will provide ratings of their stress using 0-10 scales

    Time frame: Change from baseline to approx. 40 minutes after CBG/placebo use

  6. Change in Stress

    Participants will provide ratings of their stress using 0-10 scales

    Time frame: Change from baseline to approx. 60 minutes after CBG/placebo use

  7. Change in Anxiety

    Participants will provide ratings of their anxiety using 0-10 scales and will complete the State Form of the State-Trait Anxiety Inventory

    Time frame: Change from baseline to approx. 20 minutes after CBG/placebo use

  8. Change in Anxiety

    Participants will provide ratings of their anxiety using 0-10 scales and will complete the State Form of the State-Trait Anxiety Inventory

    Time frame: Change from baseline to approx. 40 minutes after CBG/placebo use

  9. Change in Anxiety

    Participants will provide ratings of their anxiety using 0-10 scales and will complete the State Form of the State-Trait Anxiety Inventory

    Time frame: Change from baseline to approx. 60 minutes after CBG/placebo use

Secondary outcomes

  1. Memory

    Participants will complete the California Verbal Learning Test II (alternate forms)

    Time frame: Approx. 40 minutes after ingesting CBG/Placebo

  2. Psychomotor

    Participants will complete the DRUID app

    Time frame: Change from baseline to approx. 45 minutes after ingesting CBG/Placebo

  3. Change in Potential Side Effects (dry mouth, dry eyes, sleepiness, increased appetite, intoxication, heart palpitations/racing heart)

    Participants will provide ratings of each potential side effect using 0-10 scales

    Time frame: Change from baseline to approx. 20 minutes after ingesting CBG/Placebo

  4. Change in Potential Side Effects (dry mouth, dry eyes, sleepiness, increased appetite, intoxication, heart palpitations/racing heart)

    Participants will provide ratings of each potential side effect using 0-10 scales

    Time frame: Change from baseline to approx. 40 minutes after ingesting CBG/Placebo

  5. Change in Potential Side Effects (dry mouth, dry eyes, sleepiness, increased appetite, intoxication, heart palpitations/racing heart)

    Participants will provide ratings of each potential side effect using 0-10 scales

    Time frame: Change from baseline to approx. 60 minutes after ingesting CBG/Placebo

07

Study locations

1 site
  • Washington State University
    Pullman, Washington 99164, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified data will be shared upon request and after publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Deidentified data will be retained indefinitely

Access criteria: Researchers wanting to conduct secondary data analysis following my own publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Nov 2023, 20 months.

Of 52 non-industry phase 1 interventional studies under Anxiety Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 20 months is above that.

Counting every sponsor, half of 71 studies reached it within 14 months; a quarter within 7 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Feb 25, 2022
StartActual
Mar 24, 2022
Primary completionActual
Nov 28, 2023
CompletionActual
Nov 28, 2023
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05257044
Lead sponsor
Washington State University
Responsible party
Carrie Cuttler (Assistant Professor, Washington State University) — Principal investigator
First posted
Feb 25, 2022
Start date
Mar 24, 2022
Primary completion
Nov 28, 2023
Completion
Nov 28, 2023
Last update
Jun 2, 2026

Study contacts

Carrie Cuttler, PhD
principal investigator · Washington State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabigerol

Start the discussion